Hassan Yousefnia , Samaneh Zolghadri , Amir Reza Jalilian , Mojtaba Tajik , Mohammad Ghannadi-Maragheh
Applied Radiation and Isotopes - , 94, 260-265 -September, 2014
Publication year: 2014

Abstract

In this work, the absorbed dose to each organ of human for (166)Ho-TTHMP was evaluated based on biodistribution studies in rats by a RADAR method and was compared with (166)Ho-DOTMP as the only clinically used Ho-166 bone marrow ablative agent. The highest absorbed dose for this complex is observed in red marrow with 0.922mGy/MBq. The results show that (166)Ho-TTHMP has considerable characteristics compared to (166)Ho-DOTMP and can be a good candidate for bone marrow ablation in patients with multiple myeloma.